This study found racial and ethnic disparities in childhood and adolescent cancer survival for non-Hispanic black, non-Hispanic American Indian/Alaskan Native, non-Hispanic Asian or Pacific Islander, and Hispanic patients.
An artificial intelligence algorithm demonstrated better diagnostic performance in breast cancer detection compared to radiologists, who also saw improved performance when aided by the technology.
The key to predicting when liquid biopsy would produce clinically actionable information is the ability to image the blood brain barrier and macrophages, according to researchers.
Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.
This study suggested that the National Comprehensive Cancer Network Distress Thermometer problem list does not easily identify concerns most associated with high distress and low quality of life in women with gynecologic cancers.
This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes.
The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor.
The FDA Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab plus erlotinib demonstrated a favorable benefit and risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer.
In this study, researchers found that 59% of the participants reported at least 1 barrier to endocrine therapy adherence, though over half reported that taking endocrine therapy was a joint decision between themselves and their doctor.
This study provides the first evidence of the urinary TERT promoter mutations to be used as simple and cost-effective non-invasive biomarkers for the early detection of bladder cancer.